Kamien, Morton I.; Zang, Israel - In: Southern Economic Journal 66 (1999) 1, pp. 117-131
We propose a model to explain the recent practice of pharmaceutical firms of introducing generic substitutes for their own branded products before their patents expire. By this early introduction, a branded product’s provider seeks to establish a Stackelberg leadership role in the forthcoming...